Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?

Core Insights - Investors in Alnylam Pharmaceuticals, Inc. (ALNY) should monitor stock movements due to significant implied volatility in the options market, particularly the Dec 19, 2025 $140.00 Put option [1] Company Overview - Alnylam Pharmaceuticals holds a Zacks Rank 2 (Buy) in the Medical - Biomedical and Genetics industry, which is in the top 36% of the Zacks Industry Rank [3] - Over the last 60 days, three analysts have raised their earnings estimates for the current quarter, increasing the Zacks Consensus Estimate from earnings of $1.14 per share to $1.71 [3] Market Sentiment - The high implied volatility suggests that options traders anticipate a significant price movement for Alnylam Pharmaceuticals shares, potentially indicating an upcoming event that could lead to a major rally or sell-off [2][3] - Options traders often seek high implied volatility options to sell premium, aiming to benefit from the decay of options value if the underlying stock does not move as much as expected [4]